Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

Candesartan better than amlodipine in hypertension

By Lilian Anekwe

Candesartan has a greater effect on reducing the risk of new-onset diabetes in patients with hypertension compared with amlodipine, but the calcium channel blocker may have the greater effect in obese patients, a study has found.

The Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial found similar rates of cardiovascular disease in 4,703 hypertensive patients randomised to either candesartan or amlodipine. But patients on candesartan were 35% less likely to develop new-onset diabetes compared with those taking amlodipine.

But BMI had a significant effect on efficacy of the drugs. In patients with a BMI of at least 27.5kg/m2, the risk for death from any cause was significantly greater – at 32% - in patients on amlodipine compared to those given candesartan. The increase in new-onset diabetes was dependent on BMI for amlodipine but not for candesartan.

Study leader Dr Kazua Nakao, a researcher in evidence-based medicine at Kyoto University School of Medicine, concluded: ‘Candesartan treatment may produce significant suppression of all-cause death and reduce new-onset diabetes mellitus in patients with obesity. Results from this analysis will likely be of long-term benefit to obese hypertensive patients.'

Hypertens Res published online 13 April 2010

Rate this article  (3 average user rating)

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say